CD19 Antibody (CVID3/155), Novus Biologicals™

Mouse Monoclonal Antibody

Catalog Number	Mfr. No.	Quantity
NBP24467400	Novus Biologicals NBP2446740.02MG	0.02 mg
NBP24467401	Novus Biologicals NBP2446740.1MG	0.1 mg
NBP24467402	Novus Biologicals NBP2446740.2MG	0.2 mg

Description

Ensure accurate, reproducible results in Flow Cytometry, Immunofluorescence

CD19 Monoclonal specifically detects CD19 in Human, Monkey samples. It is validated for Flow Cytometry, Immunocytochemistry/Immunofluorescence.

Specifications

• Antigen: CD19
• Concentration: 0.2 mg/mL
• Applications: Flow Cytometry, SDS-Page, Immunofluorescence
• Conjugate: Unconjugated
• Host Species: Mouse
• Research Discipline: Adaptive Immunity, Cytokine Research, Immunology, Innate Immunity, Mesenchymal Stem Cell Markers, Signal Transduction, Stem Cell Lines, Stem Cell Markers
• Formulation: 10mM PBS and 0.05% BSA with 0.05% Sodium Azide
• Gene ID (Entrez): 930
• Immunogen: Recombinant human CD19 protein
• Primary or Secondary: Primary
• Content And Storage: Store at 4C.
• Molecular Weight of Antigen: 95 kDa

• Clone: CVID3/155
• Dilution: Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, SDS-Page, Immunofluorescence 0.5 - 1.0 ug/ml
• Classification: Monoclonal
• Form: Purified
• Regulatory Status: RUO
• Target Species: Human, Monkey
• Gene Alias: B4, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CD19 antigen, CD19 molecule, CVID3, Differentiation antigen CD19, MGC12802, T-cell surface antigen Leu-12
• Gene Symbols: CD19
• Isotype: IgG1 κ
• Purification Method: Protein A or G purified
• Test Specificity: Recognizes a protein of 95kDa, identified as CD19. CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

For Research Use Only